{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:44:27Z","timestamp":1788320667314,"version":"build-2803163510"},"reference-count":18,"publisher":"Walter de Gruyter GmbH","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2019-0784_s_999_w2aab3b8c49b1b7b1aab1c17b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Therapeutic drug monitoring (TDM) of antiepileptic drugs (AEDs) can serve as a valuable tool in optimising and individualising epilepsy treatment, especially in vulnerable groups such as pregnant women, the elderly and children. Unfortunately, TDM is often performed suboptimally due to limitations in blood collection. Therefore, we investigated volumetric absorptive micro sampling (VAMS) \u2013 a new home-sampling technique. We aimed to evaluate VAMS to determine and quantify the different AEDs and concentrations of 16 different AEDs in whole blood collected by VAMS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2019-0784_s_998_w2aab3b8c49b1b7b1aab1c17b2Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patient blood samples (n\u2009=\u2009138) were collected via venepunctures at the Academic Centre for Epileptology Kempenhaeghe. AED concentrations were determined, and these concentrations were used to compare the VAMS method (whole blood) with the conventional method (serum). In addition, the recovery was examined as well as the impact of haematocrit. Finally, AED-spiked blood was used to test the stability of the AEDs inside the micro-sampler devices over a period of time and whether temperature had an effect on the stability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2019-0784_s_997_w2aab3b8c49b1b7b1aab1c17b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>VAMS allows for an accurate detection of 16 different AEDs within 2 days after sampling. Deviation in recovery was less than 10% and high correlations were found between VAMS and conventional sampling. Moreover, haematocrit does not have an effect with values between 0.3 and 0.5 (L\/L). Finally, although storage temperature of VAMS does affect some AEDs, most are unaffected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2019-0784_s_996_w2aab3b8c49b1b7b1aab1c17b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>VAMS enables an accurate detection of a wide variety of AEDs within 2 days after sampling.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2019-0784","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T04:01:53Z","timestamp":1581393713000},"page":"828-835","source":"Crossref","is-referenced-by-count":26,"title":["Therapeutic drug monitoring of anti-epileptic drugs \u2013 a clinical verification of volumetric absorptive micro sampling"],"prefix":"10.1515","volume":"58","author":[{"given":"Thierry P.I.J.M.","family":"Canisius","sequence":"first","affiliation":[{"name":"Laboratory Clinical Chemistry and Pharmacology , Academic Centre for Epileptology Kempenhaeghe Maastricht UMC+ , VE Heeze , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.P. Hans","family":"Soons","sequence":"additional","affiliation":[{"name":"Laboratory Clinical Chemistry and Pharmacology , Academic Centre for Epileptology Kempenhaeghe Maastricht UMC+ , VE Heeze , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Verschuure","sequence":"additional","affiliation":[{"name":"Laboratory Clinical Chemistry and Pharmacology , Academic Centre for Epileptology Kempenhaeghe Maastricht UMC+ , VE Heeze , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmeke A.","family":"Wammes-van der Heijden","sequence":"additional","affiliation":[{"name":"Laboratory Clinical Chemistry and Pharmacology , Academic Centre for Epileptology Kempenhaeghe Maastricht UMC+ , VE Heeze , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob P.W.","family":"Rouhl","sequence":"additional","affiliation":[{"name":"Department of Neurology , Academic Centre for Epileptology Kempenhaeghe Maastricht UMC+ , Heeze , the Netherlands"},{"name":"School for Mental Health and Neuroscience , Maastricht University Medical Centre , Maastricht , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.J. Marian","family":"Majoie","sequence":"additional","affiliation":[{"name":"Department of Neurology , Academic Centre for Epileptology Kempenhaeghe Maastricht UMC+ , Heeze , the Netherlands"},{"name":"School for Mental Health and Neuroscience , Maastricht University Medical Centre , Maastricht , the Netherlands"},{"name":"School of Health Professions Education, Faculty of Health, Medicine and Life Sciences , Maastricht University , Maastricht , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"key":"2026043020133136324_j_cclm-2019-0784_ref_001_w2aab3b8c49b1b7b1ab2b2b1Aa","unstructured":"Organization WH. Fact-sheet epilepsy 2019 [updated 20-06-2019]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/epilepsy."},{"key":"2026043020133136324_j_cclm-2019-0784_ref_002_w2aab3b8c49b1b7b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Rho JM, White HS. Brief history of anti-seizure drug development. Epilepsia Open 2018;3:114\u20139.","DOI":"10.1002\/epi4.12268"},{"key":"2026043020133136324_j_cclm-2019-0784_ref_003_w2aab3b8c49b1b7b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008;49:1239\u201376.","DOI":"10.1111\/j.1528-1167.2008.01561.x"},{"key":"2026043020133136324_j_cclm-2019-0784_ref_004_w2aab3b8c49b1b7b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Gedzelman E, Meador KJ. Antiepileptic drugs in women with epilepsy during pregnancy. Ther Adv Drug Saf 2012;3:71\u201387.","DOI":"10.1177\/2042098611433192"},{"key":"2026043020133136324_j_cclm-2019-0784_ref_005_w2aab3b8c49b1b7b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Jacob S, Nair AB. An updated overview on therapeutic drug monitoring of recent antiepileptic drugs. Drugs R D 2016;16:303\u201316.","DOI":"10.1007\/s40268-016-0148-6"},{"key":"2026043020133136324_j_cclm-2019-0784_ref_006_w2aab3b8c49b1b7b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Tomson T, Johannessen SI. Therapeutic monitoring of the new antiepileptic drugs. Eur J Clin Pharmacol 2000;55:697\u2013705.","DOI":"10.1007\/s002280050001"},{"key":"2026043020133136324_j_cclm-2019-0784_ref_007_w2aab3b8c49b1b7b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Sourbron J, Chan H, Wammes-van der Heijden EA, Klarenbeek P, Wijnen BF, de Haan GJ, et al. Review on the relevance of therapeutic drug monitoring of levetiracetam. Seizure 2018;62:131\u20135.","DOI":"10.1016\/j.seizure.2018.09.004"},{"key":"2026043020133136324_j_cclm-2019-0784_ref_008_w2aab3b8c49b1b7b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Kr\u00e4mer G. The limitations of antiepileptic drug monotherapy. Epilepsia 1997;38:S9\u201313.","DOI":"10.1111\/j.1528-1157.1997.tb04599.x"},{"key":"2026043020133136324_j_cclm-2019-0784_ref_009_w2aab3b8c49b1b7b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Doheny HC, Whittington MA, Jefferys JG, Patsalos PN. A comparison of the efficacy of carbamazepine and the novel anti-epileptic drug levetiracetam in the tetanus toxin model of focal complex partial epilepsy. Br J Pharmacol 2002;135:1425\u201334.","DOI":"10.1038\/sj.bjp.0704606"},{"key":"2026043020133136324_j_cclm-2019-0784_ref_010_w2aab3b8c49b1b7b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Iapadre G, Balagura G, Zagaroli L, Striano P, Verrotti A. Pharmacokinetics and drug interaction of antiepileptic drugs in children and adolescents. Paediatr Drugs 2018;20:429\u201353.","DOI":"10.1007\/s40272-018-0302-4"},{"key":"2026043020133136324_j_cclm-2019-0784_ref_011_w2aab3b8c49b1b7b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Velghe S, Stove CP. Volumetric absorptive microsampling as an alternative tool for therapeutic drug monitoring of first-generation anti-epileptic drugs. Anal Bioanal Chem 2018;410:2331\u201341.","DOI":"10.1007\/s00216-018-0866-4"},{"key":"2026043020133136324_j_cclm-2019-0784_ref_012_w2aab3b8c49b1b7b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Shibata M, Hashi S, Nakanishi H, Masuda S, Katsura T, Yano I. Detection of 22 antiepileptic drugs by ultra-performance liquid chromatography coupled with tandem mass spectrometry applicable to routine therapeutic drug monitoring. Biomed Chromatogr 2012;26:1519\u201328.","DOI":"10.1002\/bmc.2726"},{"key":"2026043020133136324_j_cclm-2019-0784_ref_013_w2aab3b8c49b1b7b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Neumaier M, Watson ID. The end of laboratory medicine as we know it? Clin Chem Lab Med 2019;57:305\u20137.","DOI":"10.1515\/cclm-2018-1264"},{"key":"2026043020133136324_j_cclm-2019-0784_ref_014_w2aab3b8c49b1b7b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Launiainen T, Ojanpera I. Drug concentrations in post-mortem femoral blood compared with therapeutic concentrations in plasma. Drug Test Anal 2014;6:308\u201316.","DOI":"10.1002\/dta.1507"},{"key":"2026043020133136324_j_cclm-2019-0784_ref_015_w2aab3b8c49b1b7b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Linder C, Wide K, Walander M, Beck O, Gustafsson LL, Pohanka A. Comparison between dried blood spot and plasma sampling for therapeutic drug monitoring of antiepileptic drugs in children with epilepsy: a step towards home sampling. Clin Biochem 2017;50:418\u201324.","DOI":"10.1016\/j.clinbiochem.2016.12.008"},{"key":"2026043020133136324_j_cclm-2019-0784_ref_016_w2aab3b8c49b1b7b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"D\u2019Urso A, Rudge J, Patsalos PN, de Grazia U. Volumetric absorptive microsampling: a new sampling tool for therapeutic drug monitoring of antiepileptic drugs. Ther Drug Monit 2019;41:681\u201392.","DOI":"10.1097\/FTD.0000000000000652"},{"key":"2026043020133136324_j_cclm-2019-0784_ref_017_w2aab3b8c49b1b7b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"De Kesel PM, Lambert WE, Stove CP. Does volumetric absorptive microsampling eliminate the hematocrit bias for caffeine and paraxanthine in dried blood samples? A comparative study. Anal Chim Acta 2015;881:65\u201373.","DOI":"10.1016\/j.aca.2015.04.056"},{"key":"2026043020133136324_j_cclm-2019-0784_ref_018_w2aab3b8c49b1b7b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Faigle JW, Menge GP. Metabolic characteristics of oxcarbazepine ((R)trileptal) and their beneficial implications for enzyme induction and drug interactions. Behav Neurol 1990;3:21\u201330.","DOI":"10.1155\/1990\/917164"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/cclm\/58\/5\/article-p828.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2019-0784\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2019-0784\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:13:44Z","timestamp":1777580024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2019-0784\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,2,11]]},"published-print":{"date-parts":[[2020,4,28]]}},"alternative-id":["10.1515\/cclm-2019-0784"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2019-0784","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,11]]}}}